GeneMatrix Inc (109820) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of GeneMatrix Inc KRW 962, price KRW 1,587, upside -39.4%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch GeneMatrix Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 1,314 KRW – 21,100 KRW · fair‑value band 691.31 KRW – 1,304 KRW · the 1,587 KRW price screens above the 961.91 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow GeneMatrix in your weekly email
Every Wednesday you see whether GeneMatrix is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
GeneMatrix Inc. develops diagnostic products for various diseases in the field of molecular diagnostics.
Show more
GeneMatrix Inc. develops diagnostic products for various diseases in the field of molecular diagnostics. The company offers products for hepatitis B, hepatitis C, cervical cancer, sexually transmitted infections, respiratory infections, and gastrointestinal infections; vaccines for preventing various diseases; and new natural pharmaceutical materials for health enhancement and treatment. It also provides biochemical diagnostics, such as special chemistry and general chemistry, that includes semi and full auto analyer, and calibrators and controls. The company was founded in 2000 and is headquartered in Seongnam-si, South Korea.
Stock analysis
GeneMatrix Inc (109820) currently trades at 1,587 KRW, while our model-based Fair Value estimate is 961.91 KRW, implying the stock looks roughly 65.0% overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 989.27 KRW per share, and 0 of the 7 models we run sit above the 1,587 KRW price.
Bear case: the Asset-Based group reads lowest at 586.33 KRW, and 7 of the 7 models stay below the price. Evidence for this calculation is low.
Scenario range: 691.31 KRW (bear) to 1,304 KRW (bull), the price of 1,587 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
GeneMatrix Inc reported revenue of 10.6B KRW in FY2025 versus 12.1B KRW in FY2021, a compound −3.2%/yr. Reported net income was −1.8B KRW in FY2025.
Key figures
Market cap 31.7B KRW (≈ $22.2M) · P/S ratio 5.89 · Net margin −17.2% · Return on equity −15.6% · Return on assets (EBIT) −4.9% · Operating margin −45.8% · Revenue (TTM) 4.7B KRW · Revenue growth (YoY) −5.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 44% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −39%, 109820 screens richer than that median.
Fair Value models
Bear 691.31 KRWFair Value 961.91 KRWBull 1,304 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+6.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.7%
Start year 2020 (pandemic). Over 10 years: +7.2% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
14.8% (2020) → −6.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+16.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +14.0% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 141 stocks
Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside−39% · Below median
Profitability
Return on assets−6% · Bottom 25%
Net margin (TTM)−44% · Bottom 25%
Operating margin (TTM)−46% · Bottom 25%
Growth and dividend
Revenue growth−5% · Below median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/FCF0.0× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 25
PAST (return on equity)0· sector 9
HEALTH (low debt)100· sector 95
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "GeneMatrix Inc Fair Value". https://www.fairvalue-calculator.com/stock/109820
Frequently asked questions
Is GeneMatrix Inc (109820) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 961.91 KRW versus a price of 1,587 KRW, about −39% upside (overvalued).
What is the fair value of 109820?
Our model-based fair value for GeneMatrix Inc is 961.91 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 1,587 KRW.
What is the quality score of 109820?
GeneMatrix Inc has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GeneMatrix Inc (109820)?
Our model-based price target is the fair value of 961.91 KRW (as of Sep 24, 2026) from 7 valuation models. Cautious scenario 691.31 KRW, optimistic scenario 1,304 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the GeneMatrix Inc stock forecast for 2026?
Our models put fair value at 961.91 KRW, about −39% upside versus a price of 1,587 KRW (overvalued). Cautious scenario 691.31 KRW, optimistic scenario 1,304 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of GeneMatrix Inc (109820)?
GeneMatrix Inc reported trailing-twelve-month revenue of about 4.7B KRW (latest available figure, as of Sep 24, 2026).
What growth is priced into GeneMatrix Inc (109820)?
For today's price to be fair in a discounted-cash-flow model, GeneMatrix Inc would have to grow free cash flow by +16.3 % per year for five years (discount rate 10.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -7.7 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 109820 use?
Our models discount GeneMatrix Inc at 10.1 %: a base by market capitalisation (nano), damped by beta 0.98, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For GeneMatrix Inc that is +16.3 % per year a year over ten years, using the same discount rate (10.1 %) and the same formula as our fair value.
How much growth has GeneMatrix Inc (109820) delivered so far?
Over the past 5 years revenue at GeneMatrix Inc grew -7.7 % a year. The price currently implies +16.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of GeneMatrix Inc (109820) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into GeneMatrix Inc (+16.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of GeneMatrix Inc (109820)?
The free-cash-flow yield on the price is 3.87 %: that much free cash flow GeneMatrix Inc produces per unit of market value. When it exceeds the discount rate of our models (10.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of GeneMatrix Inc (109820)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GeneMatrix Inc it is 961.91 KRW per share (as of Sep 24, 2026), against a price of 1,587 KRW. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is GeneMatrix Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 109820 trades above its calculated fair value: price 1,587 KRW, fair value 961.91 KRW, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 109820?
No. The price is what the market pays today (1,587 KRW); the fair value is what the company's own numbers justify (961.91 KRW). For GeneMatrix Inc the two are 625.09 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is GeneMatrix Inc worth?
The market values GeneMatrix Inc at about 31.7B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 1,587 KRW; our models calculate a fair value of 961.91 KRW per share.
What do the bullish and bearish scenarios say about 109820?
Our models span a range for GeneMatrix Inc: cautious scenario 691.31 KRW, base 961.91 KRW, optimistic 1,304 KRW per share (as of Sep 24, 2026, price 1,587 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of GeneMatrix Inc (109820)?
Balance-sheet figures for GeneMatrix Inc (as of Sep 24, 2026): return on equity −15.6%. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is 109820 from its 52-week high?
GeneMatrix Inc trades at 1,587 KRW, about 44% below its 52-week high of 2,840 KRW and 21% above the low of 1,314 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 961.91 KRW is for.
Which stocks are comparable to GeneMatrix Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GeneMatrix Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 1,587 KRW, calculated fair value 961.91 KRW (−39%), Quality Score 60/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 109820 calculated?
We run GeneMatrix Inc through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 961.91 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. GeneMatrix Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GeneMatrix Inc (109820)?
The closing price on Sep 23, 2026 was 1,587 KRW. Our model-based fair value is 961.91 KRW, about −39% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GeneMatrix Inc right now?
The price sits above even our optimistic bull case (1,304 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (691.31 KRW to 1,304 KRW) leaves room in how you read the outcome.
Key figures of GeneMatrix Inc
How large is the market capitalisation of GeneMatrix Inc (109820)?
The market capitalisation of GeneMatrix Inc is 31.7B KRW (≈ $22.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of GeneMatrix Inc (109820)?
The price-to-sales ratio of GeneMatrix Inc is 5.89 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of GeneMatrix Inc (109820)?
The net margin of GeneMatrix Inc is −17.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of GeneMatrix Inc (109820)?
The return on equity (ROE) of GeneMatrix Inc is −15.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GeneMatrix Inc (109820)?
On an EBIT basis the return on assets of GeneMatrix Inc is −4.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of GeneMatrix Inc (109820)?
The operating margin of GeneMatrix Inc is −45.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at GeneMatrix Inc (109820)?
Revenue at GeneMatrix Inc is growing −5.4% versus a year earlier (3y avg −1.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does GeneMatrix Inc (109820) carry?
The net debt of GeneMatrix Inc is 1.3B KRW (fiscal year 2025, ≈ 1.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch GeneMatrix Inc in the live analysis
One click puts GeneMatrix Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
